



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : C12N 15/00, C12P 21/00		A1	(11) International Publication Number: WO 91/00347 (43) International Publication Date: 10 January 1991 (10.01.91)
(21) International Application Number: PCT/DK89/00168		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent)*, DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KE, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.	
(22) International Filing Date: 4 July 1989 (04.07.89)			
(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).			
(72) Inventors: and (75) Inventors/Applicants (for US only): RASMUSSEN, Poul, Baad [DK/DK]; Aurehøjvej 19, DK-2900 Hellerup (DK), NORDFANG, Ole [DK/DK]; Selskovvej 6, DK-3400 Hillerød (DK).		Published <i>With international search report.</i>	
(74) Common Representative: NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsværd (DK).			

(54) Title: METHOD OF PRODUCING PROTEINS WITH FVIII ACTIVITY AND/OR FVIII DERIVATIVES

## (57) Abstract

In a process for producing proteins with FVIII activity and FVIII derivatives by *in vitro* culturing of mammalian cells, the culturing is carried out at temperatures below 32°C and the culturing times used are below 24 hours.

\* See back of page

#### **DESIGNATIONS OF "DE"**

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### **FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BP	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
RJ	Burma	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

METHOD OF PRODUCING PROTEINS WITH FVIII ACTIVITY AND/OR  
FVIII DERIVATIVES

The present invention relates to a method of producing 5 proteins with FVIII activity and/or FVIII derivatives by in vitro culturing of mammalian cells.

The bleeding disorder Hemophilia A is caused by the absence of Factor VIII (FVIII). FVIII is a glycoprotein which can 10 be isolated from blood plasma (US no. 4,650,858). Purified FVIII is used in the treatment of Hemophilia A. By the use of gene technology it is possible to synthesize FVIII (EPO 160,457, WO 85/01961, US 570,062). The amount of FVIII, which can be produced in mammalian cells is rather low 15 compared with other human proteins. The amount of protein can be increased if truncated variants of FVIII are biosynthesized (WO 86/06101, DK 3442/87), or if the two subunits (FVIII heavy chain and FVIII light chain) are co-produced (US 822,989). It is also possible in vitro to 20 assemble active FVIII from separately produced subunits (DK 2957/86). The above-mentioned forms of FVIII all have the characteristics of human FVIII: activity in bioassays, activatable by thrombin, and biological activity in hemophilia dogs.

25

Mammals are in part characterized by the ability to keep a constant body temperature near 37°C. Therefore mammalian cells in general are grown in vitro at 37°C. FVIII circulates in the body at that temperature, and by 30 culturing in serum containing medium (which mimic body fluid) one may expect that FVIII has optimal stability. FVIII produced in serum free medium is rather unstable, but nevertheless it is attractive to omit serum from the medium, and WO 87/04187 shows that FVIII can be stabilized 35 in serum free medium by addition of the carrier protein von Willebrand Factor (vWF). DK 3594/87 shows that FVIII

can also be stabilized in serum free medium by addition of lipoproteins. These stabilizing agents exhibit no pronounced effect in serum containing medium.

5 It has surprisingly been found that by culturing mammalian cells at a temperature below 37°C, more precisely below 33°C, the yields of truncated FVIII variants and of FVIII derived subunits (especially FVIII heavy chain) are increased drastically, both in serum containing and in 10 serum free medium.

It is preferred to carry out the culturing at a temperature from 10 to 32°C, more preferred at a temperature from 25 to 30°C, and most preferred at 27°C.

15

Furthermore it has surprisingly appeared that the yields are raised by shortening the medium residence time below the usual 24-72 hours, which normally gives the optimal yields from mammalian cells.

20

It is preferred to use a medium residence time of 30 hours or below, more preferred 24 hours or below, even more preferred 10 hours or below, and most preferred below 4 hours.

25

The combined effect of low growth temperature and short medium residence time is especially pronounced in the case of FVIII heavy chain for which the yield can be raised 25 times.

30

The increased yield of FVIII heavy chain (HC) at low temperature and short medium residence time can be related to instability of the product at normal growth conditions. Table 1 shows that FVIII heavy chain at 37°C loses the 35 ability to combine with FVIII light chain. Fig. 1 shows that FVIII heavy chain form aggregates at 37°C. These

aggregates can be dissolved upon reduction. Truncated variants of FVIII may behave like FVIII-HC and form aggregates at high temperature. However, the increased yield at low temperature may also be caused by other 5 factors than a decrease in aggregation. For example a greater resistance against proteolytic degradation might be important.

The preferred host cells will include mammalian cells such 10 as CHO cells, COS-7 monkey cells, melanoma cell lines such as Bowes cells, mouse L-929 cells 3T3 lines, Balb-c or NIH mice, BHK or HAK hamster cell lines and the like.

The examples show that the yields of truncated FVIII 15 variants, FVIII heavy chain, FVIII light chain and FVIII obtained from cells cotransfected with plasmids encoding each of the two subunits are increased at low temperature.

Table 1

Lane	Incubation of FVIII-HC sample	Treatment for SDS-PAGE (Fig. 1)	Combination capacity for diluted sample, FVIII:C mU/ml
5	0 h, 37°C	reduced	
6	4 h, 37°C	-	
7	26 h, 37°C	-	
8	0 h, 37°C	unreduced	10.4
9	4 h, 37°C	-	4.0
10	26 h, 37°C	-	<0.5
11	26 h, 22°C	unreduced	8.3
12	4 h, 22°C	-	8.6
13	0 h, 22°C	-	10.6
14	26 h, 22°C	reduced	
15	4 h, 22°C	-	
16	0 h, 22°C	-	
19	MW markers		

Plasma derived FVIII-HC (300 U/ml) was diluted 4 fold in 0.05% BSA, 50 mM tris, 0.1 M Nacl, 0.02% NaN<sub>3</sub>, 150 µM 2-ME, pH 7.4 and incubated at 22°C and 37°C. At t=0, 4, 24 h samples were freezed at -80°C. The samples were thawed and 5 analysed (unboiled) reduced and unreduced in Western blot Furthermore, the samples were diluted 300 fold and tested for combination with FVIII-LC (WO 88/00210).

The invention is further explained with reference to the 10 drawings in which Fig. 1 shows Western blot of FVIII-HC incubated at 22°C and 37°C (samples are the same as in Table 1).

Description of plasmids

15	<u>Plasmid</u>	<u>Description</u>
	pPR49	cDNA encoding a Factor VIII variant, in which 880 amino acids are deleted in the B-region (the variant is identical to the one encoded by the pLA-2 plasmid in PCT Patent Application, Publication no. WO 86/06101), has been inserted into the expression vector pSV7d (Truett et al., 1985, DNA 4; 333-349).
20		
	pPR60	cDNA encoding a Factor VIII variant, in which Arg-740 has been fused directly to Ser-1690, has been inserted into pSV7d.
25		
	pSVF8-92E	cDNA encoding the Factor VIII derived 92 kD peptide (heavy chain) has been inserted into pSV7d.
30		
	pSVF8-80K	cDNA encoding the Factor VIII derived 80 kD peptide (light chain) has been inserted into pSV7d.

Example 1The effect of growth temperature on the yield of proteins with Factor VIII activity

5 The expression plasmids pPR49 and pPR60 were transfected to COS-7 monkey cells (Gluzman, 1981, Cell 23; 175-182) by usage of the calcium phosphate technique (Graham and van der Eb, 1973, Virology 52; 456-467) with the modifications described in: DNA Cloning, a Practical Approach, Vol. 10 I+II/IRL Press. (Each plasmid was totally transfected to eight 5 cm's dishes: 2 times 2 dishes determined for expression at 37°C and 27°C, respectively, in serum containing medium (10%), and the same number of dishes in serum free medium). 16 hours post transfection the media 15 were changed; half the dishes were shifted to serum free medium. 40 hours post transfection the media were changed and half the dishes were transferred to a 27°C incubator. After additional 24 hours the media were harvested and the Factor VIII activity was determined by usage of the Kabi 20 coatest chromogenic assay method. The results are listed in Table 2:

Table 2

	Plasmid	Temp. (°C)	Chromogenic activity (mU/ml/day)	
			+ serum	- serum
25	pPR49	37	1023	277
		37	1028	248
		27	1862	1051
		27	1695	977
30	pPR60	37	89	>138
		37	104	>138
		27	336	387
		27	322	401
35				

Example 2

The combined effect of low growth temperature and short medium residence time on the yield of Factor VIII heavy chain from a CHO cell line

5

The CHO (Chinese Hamster Ovary) cell line DUKX-B11 Urlaub and Chasin, 1980, PNAS 77; 4216-4220), which is mutated in the dihydrofolate reductase gene, was co-transfected with the plasmids pSVF8-92E and pSVF8-80K plus a plasmid 10 encoding the dihydrofolate reductase. (These co-transfections are described in US Patent Application No. 82,989).

Hereby a clone (10C2D2) was isolated, characterized by 15 producing 10 fold more heavy chain (HC) than light chain (LC) when it is grown at 37°C. When 10C2D2 is grown at 27°C the yield of HC is raised dramatically seen in relation to the yield of LC (see Table 3).

20 Table 3

Temp. (°C)	Culturing time (hours)	Vol.med./T-80 flask (ml)	HC:Ag* (U/ml)	LC:Ag* (U/ml)
37	24	10	3.2	0.36
27	24	10	18.4	0.28

\* HC:Ag and LC:Ag were measured in specific immuno assays 30 (Nordfang et al., 1988, Br.J.Haematol. 68; 307-312; Nordfang et al., 1985, Thromb.Haemostas. 53:346-350).

By shortening the medium residence time to only 2 hours a greater yield of HC per day is achieved (Table 4):

35

Table 4

5	Temp. (°C)	Culturing time (hours)	Vol.med./T-80 flask (ml)	HC:Ag (U/ml)	HC:Ag (U/ml/ day)
10	37	24	10	3.2	3.2
	27	24	10	18.4	18.4
10	27	2	10	7.5	90
	27	2	3	24.0	288

Example 3

15 Production of FVIII:HC in Opticell Bioreactor at 28-30°C by 10C2D2

In the Opticell bioreactor the cells are cultured on a ceramic matrix, the Opticore, and the culture media is 20 circulated through the Opticore. The oxygen content, pH, medium feed and harvest are all measured and controlled by the system.

The average medium circulation time was 5 hours (150 ml per 25 hour with a volume in the reservoir + Opticore of 750 ml). The harvest was collected at 5°C and frozen every 24 h at -80°C.

The cells were cultured at 37°C until near confluent 30 (measured by the oxygen consumption rate) and the temperature was lowered to 28-30°C for production of FVIII:HC.

The cells were kept at the production temperature for 1000 35 hours. The oxygen consumption rate decreased in a couple of hours when the temperature was lowered from 37°C to 30°C and from 30°C to 28°C, but each time the oxygen consumption rate gradually increased again. Thus the cells

could be maintained at the lower temperature even for longer than the 1000 hours.

In Table 5 the medium composition and feed/harvest volumes as well as the FVIII:HC levels for some of the harvest samples are shown.

Table 5

	Hours after temperature shift to 28-30°C	Medium	Feed/Har- vest ml/h	FVIII:HC U/ml	FVIII:HC U/day
10					
15	408	DMEH + 1% ITS + 2% FCS	100	15.1	36240
20	432	+ 2% FCS	150	10.9	39240
	456	+ 2% NCS	150	11.0	39600

25

Example 4

The effect of low growth temperature on yield of Factor VIII light chain from COS-7 monkey cells

30 An expression plasmid designated pPR77 encoding Factor VIII light chain was transfected to COS-7 cells in the same manner as described in Example 1. The plasmid was transfected to four 5 cm dishes: two times two dishes determined for expression at 37°C and 27°C, respectively. 35 The media (DMEM + 10% FCS) were changed 16 and 40 hours post transfection (at 40 hours half the dishes were transferred to a 27°C incubator). After additional 24 hours the media were harvested. The content of Factor VIII light chain was determined as described in Example 2. The 40 results are given in Table 6.

Table 6

	Temp. (°C)	LC:Ag (U/ml/day)
	37	0.33
	37	0.30
	27	1.25
	27	0.85

15

Example 5

The effect of low growth temperature on the yield of protein-complex with Factor VIII activity from CHO cells transfected with plasmids encoding each of the two subunits 20 of Factor VIII: the heavy chain and the light chain

The DHFR(-) CHO cell line DG44 (cf. G. Urlaub et al., Proc.Natl.Sci., USA 77; 4216-4220, 1980) was first transfectected with a plasmid encoding the light chain of 25 Factor VIII and the dhfr gene. By selection of DHFR(+) cells a stable light-chain producer was isolated. This new cell line was co-transfected with a plasmid encoding the heavy chain of Factor VIII (and the dhfr gene) and a plasmid encoding the neo gene (pSV2neo; P.J. Southern and 30 P. Berg, Journal of Molecular and Applied Genetics 1; 327-341, 1982). Transfectants were isolated in medium containing 700 µg Geneticin (G418 Sulphate, Gibco) per ml. Cells from the primary pool were propagated directly into medium containing 0.1 µM MTX. Cells isolated in this way 35 were seeded into two T-80 flasks, called A and B. At confluence the media (DMEM + 10% DFCS + 700 µg Geneticin/ml + 0.1 µM MTX) were changed (10 ml) and the flasks were incubated 24 hours at 37°C whereafter media samples were collected. The media were renewed and the B flask was

transferred to a 27°C incubator. Again the flasks were incubated for 24 hours followed by collection of media samples and renewing of media. This procedure was repeated for another two days (the A flask still at 37°C and the B 5 flask still at 27°C). The Factor VIII activity was determined by the Kabi coatest chromogenic assay method. The results are given in Table 7.

Table 7

	Day	Temp. (°C)	Chromogenic activity (U/ml/day)
15	<u>Flask A:</u>	1	37
		2	37
		3	37
		4	37
20	<u>Flask B:</u>	1	37
		2	27
		3	27
		4	27

**CLAIMS**

1. A method for producing proteins with FVIII activity and/or FVIII derivatives by in vitro culturing of mammalian cells, said culturing being carried out at a temperature below 33°C.
2. A method as claimed in Claim 1, wherein the temperature is from 10 to 32°C.  
10
3. A method as claimed in Claim 2, wherein the temperature is from 25 to 30°C.
4. A method as claimed in Claim 3, wherein the temperature is 27°C.  
15
5. A method as claimed in any of Claims 1-4, wherein the FVIII derivative produced is the 92.5 kD fragment or the "Heavy Chain".  
20
6. A method as claimed in any of Claims 1-4, wherein the FVIII derivative produced is the 80 kD fragment or the "Light Chain".
- 25 7. A method as claimed in any of Claims 1-4, wherein the resulting product is a protein-complex with FVIII activity obtained from cells transfected with plasmids encoding each of the two subunits of FVIII: the heavy chain and the light chain.  
30
8. A method as claimed in any of Claims 1-7, wherein the mammalian cells used are COS cells, CHO cells or BHK cells.

1/1




FIG. 1

## INTERNATIONAL SEARCH REPORT

International Application No PCT/DK89/00168

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) <sup>8</sup>  
 According to International Patent Classification (IPC) or to both National Classification and IPC<sub>4</sub>

C 12 N 15/00, C 12 P 21/00

## II. FIELDS SEARCHED

Classification System	Minimum Documentation Searched <sup>9</sup>	
	Classification	Symbols
IPC 4	C 12 N 15/00, C 07 K 15/06, A 61 K 37/02, C 12 P 21/00, C 12 P 21/02	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		

SE, NO, DK, FI classes as above. Data base search CA,WPI,WPIL.

III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>10</sup>

Category <sup>11</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	EP, A1, 0 265 778 (RORER INTERNATIONAL (OVERSEAS) INC.) 4 May 1988 see page 12, lines 50-58	1-8

- \* Special categories of cited documents: <sup>14</sup>
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" document published on or after the international filing date
  - "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (as specified)
  - "O" document referring to an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search  1989-09-21	Date of Mailing of this International Search Report  1989-10-09
International Searching Authority  Swedish Patent Office	Signature of Authorized Officer  Göran Brostean Yvonne Sibsteen